BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu B, Fan H, Lv X, Chen S, Shao Z. Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis. Cancer Cell Int. 2018;18:68. [PMID: 29743818 DOI: 10.1186/s12935-018-0562-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhu J, Zhou Y, Wang L, Hao J, Chen R, Liu L, Li J. CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma. J Gastrointest Oncol 2020;11:1364-80. [PMID: 33457007 DOI: 10.21037/jgo-20-556] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662-80. [PMID: 32753728 DOI: 10.1038/s41568-020-0285-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 88] [Article Influence: 122.0] [Reference Citation Analysis]
3 Caligiuri A, Pastore M, Lori G, Raggi C, Di Maira G, Marra F, Gentilini A. Role of Chemokines in the Biology of Cholangiocarcinoma. Cancers (Basel) 2020;12:E2215. [PMID: 32784743 DOI: 10.3390/cancers12082215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Li J, Zhang J, Hu H, Cai Y, Ling J, Wu Z, Deng Y. Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients. Cancer Manag Res 2020;12:3301-10. [PMID: 32494194 DOI: 10.2147/CMAR.S243490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH, Feng H, Zheng MH, Zhao JK, Lu AG. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer. Cell Death Dis 2019;10:178. [PMID: 30792394 DOI: 10.1038/s41419-019-1431-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 15.5] [Reference Citation Analysis]
6 Luo M, Hu Z, Kong Y, Li L. MicroRNA-432-5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer. Exp Ther Med 2021;21:301. [PMID: 33717244 DOI: 10.3892/etm.2021.9732] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khandia R, Munjal A. Interplay between inflammation and cancer. Inflammatory Disorders, Part A. Elsevier; 2020. pp. 199-245. [DOI: 10.1016/bs.apcsb.2019.09.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
8 Saunders AS, Bender DE, Ray AL, Wu X, Morris KT. Colony-stimulating factor 3 signaling in colon and rectal cancers: Immune response and CMS classification in TCGA data. PLoS One 2021;16:e0247233. [PMID: 33606788 DOI: 10.1371/journal.pone.0247233] [Reference Citation Analysis]
9 Bendell J, Sharma S, Patel MR, Windsor KS, Wainberg ZA, Gordon M, Chaves J, Berlin J, Brachmann CB, Zavodovskaya M, Liu J, Thai D, Bhargava P, Shah MA, Khan SA, Starodub A. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. Oncologist 2020;25:954-62. [PMID: 32812320 DOI: 10.1634/theoncologist.2020-0474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Novillo A, Gaibar M, Romero-Lorca A, Gilsanz MF, Beltrán L, Galán M, Antón B, Malón D, Moreno A, Fernández-Santander A. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World J Gastroenterol 2020;26:1979-86. [PMID: 32390708 DOI: 10.3748/wjg.v26.i16.1979] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Da Z, Gao L, Su G, Yao J, Fu W, Zhang J, Zhang X, Pei Z, Yue P, Bai B, Lin Y, Meng W, Li X. Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma. Cancer Cell Int 2020;20:130. [PMID: 32336950 DOI: 10.1186/s12935-020-01212-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Jiao L, Wei J, Ye J, Zhang C. Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study. Dis Markers 2021;2021:9508702. [PMID: 33747258 DOI: 10.1155/2021/9508702] [Reference Citation Analysis]
13 Ruiz-Plazas X, Rodríguez-Gallego E, Alves M, Altuna-Coy A, Lozano-Bartolomé J, Portero-Otin M, García-Fontgivell JF, Martínez-González S, Segarra J, Chacón MR. Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness. J Transl Med 2019;17:307. [PMID: 31500625 DOI: 10.1186/s12967-019-2053-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Cagliani R, Gatto F, Cibecchini G, Marotta R, Catalano F, Sanchez-Moreno P, Pompa PP, Bardi G. CXCL5 Modified Nanoparticle Surface Improves CXCR2+ Cell Selective Internalization. Cells 2019;9:E56. [PMID: 31878341 DOI: 10.3390/cells9010056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Yin X, Zhang Y, Wen Y, Yang Y, Chen H. Celecoxib alleviates zinc deficiency-promoted colon tumorigenesis through suppressing inflammation. Aging (Albany NY) 2021;13:8320-34. [PMID: 33686969 DOI: 10.18632/aging.202642] [Reference Citation Analysis]
16 Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, Li M, Shuoa SM, You Q, Miao L. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun (Lond) 2020;40:69-80. [PMID: 32237072 DOI: 10.1002/cac2.12010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]